Samad A. Sam's Insider Trades & SAST Disclosures
Samad A. Sam's most recent trade in Idexx Laboratories, Inc. was a trade of 600 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on May 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Samad A. Sam.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 600 | 600 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 257 | 257 | - | - | Deferred Stock Unit | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | 21 Apr 2025 | 74 | 26,451 (0%) | 0% | 164.4 | 12,167 | Common Stock | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 04 Mar 2025 | 13,884 | 34,061 (0%) | 0% | 173.7 | 2,412,206 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 04 Mar 2025 | 7,684 | 26,377 (0%) | 0% | 173.7 | 1,335,018 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 869 | 20,177 (0%) | 0% | 171.8 | 149,251 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 1,031 | 21,046 (0%) | 0% | 169.7 | 174,971 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 17,403 | 17,403 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,538 | 22,077 (0%) | 0% | 0 | Common Stock | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | 29 Jan 2025 | 35 | 17,539 (0%) | 0% | 158.0 | 5,531 | Common Stock | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | 21 Oct 2024 | 37 | 17,504 (0%) | 0% | 149.4 | 5,527 | Common Stock | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | 22 Jul 2024 | 21 | 17,467 (0%) | 0% | 147.0 | 3,086 | Common Stock | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.65 per share. | 16 Jul 2024 | 3,910 | 17,446 (0%) | 0% | 142.7 | 557,762 | Common Stock |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 609 | 609 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 262 | 863 | - | - | Deferred Stock Unit | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 126.25 per share. | 22 Apr 2024 | 24 | 21,356 (0%) | 0% | 126.3 | 3,030 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 656 | 21,332 (0%) | 0% | 126.4 | 82,892 | Common Stock |
| Quest Diagnostics, Inc. | Samad A. Sam | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 22,835 | 22,835 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Quest Diagnostics, Inc. | Samad Sam A. | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,478 | 21,988 (0%) | 0% | 0 | Common Stock | |
| Quest Diagnostics, Inc. | Samad A. Sam | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 129.35 per share. | 31 Jan 2024 | 17 | 16,510 (0%) | 0% | 129.4 | 2,199 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 122.89 per share. | 23 Oct 2023 | 18 | 16,493 (0%) | 0% | 122.9 | 2,212 | Common Stock |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.18 per share. | 14 Jul 2023 | 3,909 | 16,475 (0%) | 0% | 140.2 | 547,964 | Common Stock |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 645 | 645 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 257 | 601 | - | - | Deferred Stock Unit | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 18,616 | 18,616 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Quest Diagnostics, Inc. | Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,710 | 20,384 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 945 | 945 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 344 | 344 | - | - | Deferred Stock Unit | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 6,246 | 6,246 | - | - | Performance Shares | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 2,082 | 11,297 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 4,561 | 11,023 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 4,561 | 0 | - | - | Performance Shares | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 319.86 per share. | 22 Feb 2022 | 1,808 | 9,215 (0%) | 0% | 319.9 | 578,307 | Common Stock |
| Illumina Inc | Sam A. Samad | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 408.14 per share. | 05 Nov 2021 | 723 | 6,462 (0%) | 0% | 408.1 | 295,085 | Common Stock |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 723 | 723 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Sam A. Samad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 224 | 887 | - | - | Deferred Stock Unit | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 4,379 | 0 | - | - | Performance Shares | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2021 | 4,379 | 9,355 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 494.24 per share. | 17 Feb 2021 | 2,170 | 7,185 (0%) | 0% | 494.2 | 1,072,501 | Common Stock |
| Illumina Inc | Sam A. Samad | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 482 | 4,976 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 4,140 | 4,140 | - | - | Performance Shares | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2021 | 1,380 | 4,494 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Sam A. Samad | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 376.55 per share. | 06 Jan 2021 | 214 | 3,114 (0%) | 0% | 376.6 | 80,582 | Common Stock |
| Illumina Inc | Sam A Samad | SVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.72 per share. | 05 Nov 2020 | 551 | 3,328 (0%) | 0% | 311.7 | 171,758 | Common Stock |
| Illumina Inc | Sam A Samad | SVP and CFO | Sale of securities on an exchange or to another person at price $ 360.00 per share. | 26 May 2020 | 1,356 | 3,879 (0%) | 0% | 360 | 488,160 | Common Stock |
| Illumina Inc | Sam A Samad | SVP and CFO | Sale of securities on an exchange or to another person at price $ 340.00 per share. | 18 May 2020 | 1,357 | 5,235 (0%) | 0% | 340 | 461,380 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges